Southern Iron Disorders Center, Birmingham, Alabama, USA.
Clin Gastroenterol Hepatol. 2012 Apr;10(4):412-6. doi: 10.1016/j.cgh.2011.11.032. Epub 2012 Jan 17.
BACKGROUND & AIMS: We investigated the risk of death from iron overload among treated hemochromatosis probands who were homozygous for HFE C282Y and had serum levels of ferritin greater than 1000 μg/L at diagnosis.
We compared serum levels of ferritin at diagnosis and other conditions with the rate of iron overload-associated death using data from 2 cohorts of probands with hemochromatosis who were homozygous for HFE C282Y (an Alabama cohort, n = 294, 63.9% men and an Ontario cohort, n = 128, 68.8% men). We defined iron overload-associated causes of death as cirrhosis (including hepatic failure and primary liver cancer) caused by iron deposition and cardiomyopathy caused by myocardial siderosis. All probands received phlebotomy and other appropriate therapy.
The mean survival times after diagnosis were 13.2 ± 7.3 y and 12.5 ± 8.3 y in Alabama and Ontario probands, respectively. Serum levels of ferritin greater than 1000 μg/L at diagnosis were observed in 30.1% and 47.7% of Alabama and Ontario probands, respectively. In logistic regressions of serum ferritin greater than 1000 μg/L, there were significant positive associations with male sex and cirrhosis in Alabama probands and with age, male sex, increased levels of alanine and aspartate aminotransferases, and cirrhosis in Ontario probands. Of probands with serum levels of ferritin greater than 1000 μg/L at diagnosis, 17.9% of those from Alabama and 14.8% of those from Ontario died of iron overload. Among probands with serum levels of ferritin greater than 1000 μg/L, the relative risk of iron overload-associated death was 5.4 for the Alabama group (95% confidence interval [CI], 2.2-13.1; P = .0002) and 4.9 for the Ontario group (95% CI, 1.1-22.0; P = .0359).
In hemochromatosis probands homozygous for HFE C282Y, serum levels of ferritin greater than 1000 μg/L at diagnosis were positively associated with male sex and cirrhosis. Even with treatment, the relative risk of death from iron overload was 5-fold greater in probands with serum levels of ferritin greater than 1000 μg/L.
我们研究了在诊断时血清铁蛋白水平大于 1000μg/L 且为 HFE C282Y 纯合子的治疗性血色病患者中,铁过载相关死亡的风险。
我们比较了铁过载相关死亡的发生率与两个铁代谢紊乱 C282Y 纯合子患者队列(阿拉巴马队列,n=294,男性占 63.9%;安大略队列,n=128,男性占 68.8%)的诊断时血清铁蛋白水平和其他情况。我们将铁过载相关死亡原因定义为铁沉积引起的肝硬化(包括肝衰竭和原发性肝癌)和心肌含铁血黄素沉着症引起的心肌病。所有患者均接受了放血治疗和其他适当的治疗。
在阿拉巴马和安大略队列中,患者诊断后的平均生存时间分别为 13.2±7.3 年和 12.5±8.3 年。在阿拉巴马和安大略队列中,分别有 30.1%和 47.7%的患者诊断时血清铁蛋白水平大于 1000μg/L。在阿拉巴马队列中,男性和肝硬化与铁蛋白大于 1000μg/L 呈显著正相关;在安大略队列中,年龄、男性、丙氨酸转氨酶和天门冬氨酸转氨酶水平升高与肝硬化与铁蛋白大于 1000μg/L 呈显著正相关。在诊断时血清铁蛋白水平大于 1000μg/L 的患者中,17.9%的阿拉巴马患者和 14.8%的安大略患者死于铁过载。在血清铁蛋白水平大于 1000μg/L 的患者中,阿拉巴马组铁过载相关死亡的相对风险为 5.4(95%置信区间[CI]:2.2-13.1;P=0.0002),安大略组为 4.9(95%CI:1.1-22.0;P=0.0359)。
在 HFE C282Y 纯合子血色病患者中,诊断时血清铁蛋白水平大于 1000μg/L 与男性和肝硬化呈正相关。即使接受治疗,铁蛋白水平大于 1000μg/L 的患者死于铁过载的相对风险仍增加 5 倍。